BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18081229)

  • 21. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J
    Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
    Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
    Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of heterozygosity and methylation of p16 in renal cell carcinoma.
    Sanz-Casla MT; Maestro ML; del Barco V; Zanna I; Moreno J; Vidaurreta M; Almansa I; Fernández C; Blanco J; Maestro C; Resel L
    Urol Res; 2003 Jul; 31(3):159-62. PubMed ID: 12883879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
    Spanakis NE; Gorgoulis V; Mariatos G; Zacharatos P; Kotsinas A; Garinis G; Trigidou R; Karameris A; Tsimara-Papastamatiou H; Kouloukousa M; Manolis EN; Kittas C
    Anticancer Res; 1999; 19(3A):1893-9. PubMed ID: 10470133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p16INK4A gene alterations are not a prognostic indicator for survival in patients with hepatocellular carcinoma undergoing curative hepatectomy.
    Anzola M; Cuevas N; Lopez-Martinez M; Martinez de Pancorbo M; Burgos JJ
    J Gastroenterol Hepatol; 2004 Apr; 19(4):397-405. PubMed ID: 15012776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.
    van Beerendonk HM; Rozeman LB; Taminiau AH; Sciot R; Bovée JV; Cleton-Jansen AM; Hogendoorn PC
    J Pathol; 2004 Mar; 202(3):359-66. PubMed ID: 14991902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence.
    Friedrich MG; Blind C; Milde-Langosch K; Erbersdobler A; Conrad S; Löning T; Hammerer P; Huland H
    Eur Urol; 2001 Nov; 40(5):518-24. PubMed ID: 11752859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma.
    Attri J; Srinivasan R; Majumdar S; Radotra BD; Wig J
    BMC Gastroenterol; 2005 Jun; 5():22. PubMed ID: 15985168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia.
    Kresty LA; Mallery SR; Knobloch TJ; Song H; Lloyd M; Casto BC; Weghorst CM
    Cancer Res; 2002 Sep; 62(18):5295-300. PubMed ID: 12234999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer.
    Tam KW; Zhang W; Soh J; Stastny V; Chen M; Sun H; Thu K; Rios JJ; Yang C; Marconett CN; Selamat SA; Laird-Offringa IA; Taguchi A; Hanash S; Shames D; Ma X; Zhang MQ; Lam WL; Gazdar A
    J Thorac Oncol; 2013 Nov; 8(11):1378-88. PubMed ID: 24077454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas.
    Wong DJ; Barrett MT; Stöger R; Emond MJ; Reid BJ
    Cancer Res; 1997 Jul; 57(13):2619-22. PubMed ID: 9205067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inactivation of p16INK4a by CpG hypermethylation is not a frequent event in colorectal cancer.
    Norrie MW; Hawkins NJ; Todd AV; Meagher AP; O'Connor TW; Ward RL
    J Surg Oncol; 2003 Nov; 84(3):143-50. PubMed ID: 14598358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modes of silencing of p16 in development of esophageal squamous cell carcinoma.
    Tokugawa T; Sugihara H; Tani T; Hattori T
    Cancer Res; 2002 Sep; 62(17):4938-44. PubMed ID: 12208744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic alterations in gallbladder adenoma, dysplasia and carcinoma.
    Kim YT; Kim J; Jang YH; Lee WJ; Ryu JK; Park YK; Kim SW; Kim WH; Yoon YB; Kim CY
    Cancer Lett; 2001 Aug; 169(1):59-68. PubMed ID: 11410326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of chromosome 9p21 and decreased p16 expression correlate with malignant gastrointestinal stromal tumor.
    Zhang Y; Cao H; Wang M; Zhao WY; Shen ZY; Shen DP; Ni XZ; Wu ZY; Shen YY; Song YY
    World J Gastroenterol; 2010 Oct; 16(37):4716-24. PubMed ID: 20872974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China.
    Xing EP; Nie Y; Wang LD; Yang GY; Yang CS
    Carcinogenesis; 1999 Jan; 20(1):77-84. PubMed ID: 9934853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke-related cholangiocarcinoma.
    Chinnasri P; Pairojkul C; Jearanaikoon P; Sripa B; Bhudhisawasdi V; Tantimavanich S; Limpaiboon T
    Hum Pathol; 2009 Jun; 40(6):817-26. PubMed ID: 19200577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
    Ryan A; Al-Jehani RM; Mulligan KT; Jacobs IJ
    Gynecol Oncol; 1998 Jan; 68(1):14-7. PubMed ID: 9454653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High prevalence of p16 genetic alterations in head and neck tumours.
    Miracca EC; Kowalski LP; Nagai MA
    Br J Cancer; 1999 Oct; 81(4):677-83. PubMed ID: 10574255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p16 is a major inactivation target in hepatocellular carcinoma.
    Jin M; Piao Z; Kim NG; Park C; Shin EC; Park JH; Jung HJ; Kim CG; Kim H
    Cancer; 2000 Jul; 89(1):60-8. PubMed ID: 10897001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.